Betahistine for Tinnitus: Prescribed, but Weakly Supported

Betahistine is one of the most widely prescribed drugs for tinnitus and dizziness-related conditions in parts of Europe — and one where the honest evidence picture is notably weaker than its prescribing volume would suggest. This is worth covering directly, since it's likely to come up if you search for medication options.

What it is and why it's prescribed

Betahistine is a drug originally developed for Ménière's disease — a condition involving vertigo, fluctuating hearing loss, tinnitus, and ear fullness. It works on histamine receptors and is thought to increase blood circulation in the inner ear, the rationale behind its use for tinnitus specifically. It's important to know upfront: it is not licensed for tinnitus treatment in the UK, and per NICE's own review, there is currently no clinically proven drug treatment for tinnitus at all — betahistine's use for tinnitus specifically has always been somewhat off-label reasoning extended from its Ménière's disease indication.

What the evidence review actually found

The UK's National Institute for Health and Care Excellence (NICE), whose evidence reviews this site treats as a strong, non-commercial evidence standard, conducted a formal review specifically asking whether betahistine is clinically and cost-effective for tinnitus. The conclusion is direct: the evidence showed no clinical difference between betahistine and placebo, with some possible harm shown specifically in people with tinnitus who did not have Ménière's disease. NICE's guidance goes further, stating that based on existing clinical evidence, betahistine would not be considered cost-effective, since it doesn't show improved health outcomes relative to its cost.

Even for Ménière's disease itself, the picture is mixed

This is a useful, honest complication: even for Ménière's disease — the condition betahistine was actually developed and approved for — the evidence is more contested than its widespread use suggests. A systematic review pooling 10 randomized controlled trials across 402 participants found no differences in hearing loss, tinnitus, or quality of life between betahistine and placebo, rating the certainty of this evidence as low to very low. A large, well-designed trial (the BEMED trial, described as adequately powered with low risk of bias) specifically found no evidence of a difference between betahistine and placebo for reducing vertigo, Ménière's disease's primary symptom. At the same time, a professional consensus conference of vestibular disorder specialists rated betahistine as useful for dizziness and vertigo specifically (87% agreement) while explicitly rating its efficacy for hearing loss, tinnitus, and ear fullness as low — a nuanced, split verdict from clinicians who use it regularly, not a blanket endorsement or rejection.

Why the gap between prescribing patterns and evidence exists

This is a genuinely interesting case of clinical practice outpacing rigorous evidence — betahistine has been used for decades, has a good general safety profile, and clinicians' accumulated experience with individual patients doesn't always align cleanly with what controlled trials measure in aggregate. That gap doesn't necessarily mean either side is wrong — it's a real, acknowledged tension in evidence-based medicine, and part of why formal bodies like NICE specifically flag drugs like this for reassessment despite continued widespread use.

What this means practically

If betahistine has been suggested to you for tinnitus specifically (rather than diagnosed Ménière's disease), it's reasonable to ask directly what outcome your prescriber expects and how that aligns with the formal evidence review findings described here — not to refuse the medication outright, since individual response can differ from population-level trial averages, but to have an honest, informed conversation about realistic expectations rather than assuming it's a well-proven tinnitus treatment.

The practical takeaway

Betahistine's tinnitus evidence is a clear example of why this site treats formal, non-commercial evidence reviews as the standard to check treatments against, rather than prescribing frequency or long-standing clinical tradition alone. It may still be tried, particularly alongside a Ménière's disease diagnosis where its rationale is stronger — but "widely prescribed" and "well-evidenced for tinnitus specifically" turn out, on close examination, to be two different things here.